Trial · NCT07885982
Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
NCT07885982, Phase 2, Not yet recruiting, Anhui Provincial Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT. Trials, record NCT07885982. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07885982
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
- NCT number
- NCT07885982
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 59 participants, estimated
- Lead sponsor
- Anhui Provincial Hospital
- Conditions
- Aplastic Anaemia
- Interventions
- Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The incidence of grade II to IV aGVHD | Day 0 to Day 100 after transplantation | The primary endpoint of the study will be the development of grade II to IV aGVHD in the first 100 days post-transplant. Acute GVHD was graded according to the Mount Sinai Acute GVHD International Consortium criteria. |
| Secondary | Incidence of Neutrophil Engraftment | Day 0 to Day 42 after transplantation | The cumulative incidence of neutrophil engraftment. Neutrophil engraftment is defined as the first of three consecutive days with an absolute neutrophil count (ANC) ≥0.5 × 10⁹/L. |
| Secondary | Incidence of Platelet Engraftment | Day 0 to Day 60 after transplantation | The cumulative incidence of platelet engraftment without platelet transfusion support. |
| Secondary | Time to Platelet Engraftment | From transplantation until platelet engraftment or Day 365 after transplantation, whichever occurs first | Time from transplantation to platelet engraftment, defined as the first of seven consecutive days with a platelet count ≥20 × 10⁹/L without platelet transfusion. |
| Secondary | Cumulative Incidence of Platelet recovery | Day 0 to Day 120 after transplantation | The cumulative incidence of platelet count ≥50 × 10⁹/L without platelet transfusion. |
| Secondary | Incidence of Grade III-IV Acute GVHD | Day 0 to Day 100 after transplantation | The proportion of participants who develop Grade III-IV acute graft-versus-host disease (aGVHD). |
| Secondary | Incidence of Chronic GVHD | Day 0 to Day 365 after transplantation | The proportion of participants who develop chronic graft-versus-host disease (cGVHD), diagnosed according to standard diagnostic criteria. |
| Secondary | Immune Reconstitution | At 1, 2, 3, 6, and 12 months after transplantation | Immune reconstitution assessed by serum immunoglobulin levels (IgA, IgG, and IgM) and lymphocyte subset analysis, including total lymphocytes, T cells, CD4⁺ T cells, CD8⁺ T cells, regulatory T cells, B cells, NK cells, activated CD4⁺ T cells, activated CD8⁺ T cells, CD8⁺ effector memory T cells, CD8⁺ effector T cells, regulatory B cells, naïve B cells, and memory B cells. |
| Secondary | Transplant-Related Mortality (TRM) | Day 0 to Day 180 after transplantation | The proportion of participants who die from causes other than disease progression or relapse following transplantation. |
| Secondary | Incidence of Infection | Day 0 to Day 365 after transplantation | The proportion of participants who develop documented bacterial, viral, or fungal infections after transplantation. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07885982
GET https://conductscience.org/api/trials/v1/NCT07885982/registered